TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/09/2024
Voltar para busca
Dado oficial do USPTO
ARGENX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
07/09/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35, 42, 44
Data de depósito
21/12/2022
Data de registro
03/09/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/09/2024
Última transação
07/09/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Zwijnaarde, BE
Examinador
KNIGHT, TROY FRANK
Unidade examinadora
L70
Localização atual
PETITIONS OFFICE
Descrição da marca
The mark consists of the word "ARGENX" in lowercase in dark gray followed by a V-shaped design, the left segment in dark green and the right segment in green, positioned above a circle in green.
Titulares e representantes
Titulares
argenx B.V.
Representantes
Edward T. White Williams Mullen
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system
Classe 35
Wholesale and retail store services for pharmaceutical preparations in the field of immunology and autoimmune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; marketing services and patient information services namelyproviding consumer product information in the field of immunologydiseases of the immune system and antibody therapeutics; provision of customer or patient informationproviding consumer product information relating to pharmaceuticalmedicalhealthcare products through an online computer network; administration of patient reimbursement programs
Classe 42
Research and development in the field of immunologyantibody engineering and autoimmune diseases; drug research and development in the field of immunologyantibody technology and autoimmune diseases; scientific and technological servicesresearchdesignanalysistesting in the field of immunityautoimmune diseases and antibody engineering; providing medical and scientific research information in the field of pharmaceuticalsclinical trialsresearch and development
Classe 44
Providing information to patients in the field of auto-immuneantibody-mediatedneuromuscularhematologicalinflammatoryrespiratorykidneyskintransplantation-related diseases and disorderscancer and diseases of the immune system and the treatment thereof; medical consultancy and medical information services relating to biopharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/09/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
03/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/09/2024
CHPB
POST PUBLICATION AMENDMENT - ENTERED
12/07/2024
APET
ASSIGNED TO PETITION STAFF
10/07/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/06/2024
PUBO
PUBLISHED FOR OPPOSITION
18/06/2024
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
10/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/05/2024
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
15/05/2024
GNSI
INQUIRY TO SUSPENSION E-MAILED
15/05/2024
CNSI
SUSPENSION INQUIRY WRITTEN
15/05/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/04/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
22/04/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
19/04/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
19/10/2023
GNSL
LETTER OF SUSPENSION E-MAILED
19/10/2023
CNSL
SUSPENSION LETTER WRITTEN
19/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/07/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/06/2023
GNRT
NON-FINAL ACTION E-MAILED
06/06/2023
CNRT
NON-FINAL ACTION WRITTEN
06/06/2023
DOCK
ASSIGNED TO EXAMINER
04/05/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
19/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/01/2023
NWAP
NEW APPLICATION ENTERED
24/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ARGENX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.